OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1061 / 1061
页数：1
相关论文
共 50 条
  • [31] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [32] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
    Wei, Fang
    An, Juan
    Hua, Yichun
    Ding, Xiaosheng
    Sun, Shibin
    Li, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [34] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
    Nguyen, D.
    Besse, B.
    Cho, B. C.
    Lee, S. -H.
    Lee, K. H.
    Lu, S.
    Cheng, Y.
    Yao, Y.
    Girard, N.
    Lin, C. -C.
    Felip, E.
    Aguilar, A.
    Charoentum, C.
    Cruz, F. J. S. M.
    Majem, M.
    Lim, C. S.
    Akamatsu, H.
    Hayashi, H.
    Yang, J. C. -H.
    Kowalyszyn, R.
    Tiscoski, K.
    Franke, F.
    Ponomarenko, D.
    Arslan, C.
    Forster, M.
    Urban, D.
    Misch, D.
    Delmonte, A.
    Montes, L. V. G.
    Gadgeel, S. M.
    Cruz-Correa, M.
    Peguero, J.
    Rousey, S.
    Gaffar, Y.
    Owen, S.
    Schuchard, J.
    Diels, J.
    Sermon, J.
    Sun, T.
    Ennis, M.
    Fennema, E.
    Daksh, M.
    Sethi, S.
    Bauml, J. M.
    Garcia Campelo, M. R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
  • [35] Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
    Ng, I.
    Kumarakulasinghe, N.
    Syn, N.
    Teng, R.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2208 - S2209
  • [36] Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs
    Rossi, Sabrina
    Toschi, Luca
    Finocchiaro, Giovanna
    D'Argento, Ettore
    Di Noia, Vincenzo Pio
    Cassano, Alessandra
    Bonomi, Maria
    Cerchiaro, Eleonora
    Ceresoli, Giovanni Luca
    Beretta, Giordano D.
    Barone, Carlo
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [38] Establishment and characterization of an EGFR-mutant NSCLC XPDX model representing first-line osimertinib resistance through an acquired TRIM24-BRAF fusion
    Moriarty, A.
    Flores, J.
    Stackpole, A.
    Ulmer, S.
    Papadopoulos, K.
    Patnaik, A.
    Rasco, D.
    Calvo, E.
    Moreno, V.
    Wick, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S111 - S111
  • [39] A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC
    Cortiula, F.
    Naidoo, J.
    LUNG CANCER, 2023, 181
  • [40] Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat
    Zugazagoitia, Jon
    Ferrer, Irene
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2016, 17 (12): : 1622 - 1623
12345